# Give subcutaneous immunotherapy in community clinics and at home

Source: https://onco.cc/ideas/idea-cost-subcutaneous-community/  
OnCo record `idea-cost-subcutaneous-community` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Under-the-skin versions of atezolizumab, nivolumab and pembrolizumab take minutes rather than an hour and need no infusion chair, so they can be given by a nurse near home, cutting facility fees and travel.

## Summary

The FDA approved subcutaneous atezolizumab (2024), nivolumab (2024) and pembrolizumab (2025), each with hyaluronidase to allow a large-volume injection over a few minutes. The clinical benefit is equivalent; the economic benefit depends on where the injection is given. Delivered in a community clinic or by a home-visiting nurse, the injection avoids hospital facility fees, infusion-suite capacity and long journeys. Payment rules that require an infusion setting, and the drug's Part B status, currently blunt the saving.

## Fields

- Kind: Idea
- Last checked: 2026-09-10
- Hypothesis: Community or home administration of subcutaneous checkpoint inhibitors will cut per-dose administration and patient travel costs by more than half against hospital infusion, with equal safety and adherence.
- Rationale: Subcutaneous trastuzumab and rituximab have been given in community settings in Europe for a decade; the barrier is payment policy, not clinical.
- Proposed test: A randomised or stepped comparison of hospital versus community administration on cost, time, patient-reported burden and adverse events.
- Maturity: early-clinical
- Actor: clinic

## Sources

- FDA: Drugs@FDA approved labels: https://www.accessdata.fda.gov/scripts/cder/daf/

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- bottlenecks: [Fragmented care and guideline gaps](https://onco.cc/bottlenecks/b-care-fragmentation/), [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Not enough oncologists, nurses, pathologists, physicists](https://onco.cc/bottlenecks/b-workforce/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- key papers: [CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy](https://onco.cc/key-papers/paper-checkmate-017-nejm-2015/), [KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation](https://onco.cc/key-papers/paper-keynote-189-nejm-2018/), [NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients](https://onco.cc/key-papers/paper-niche-2-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/idea-cost-subcutaneous-community.json